Biggest News Aggregation in the World
📰 Advanced Prostate News

Page 2 - Advanced Prostate News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Advanced Prostate. Real-time updates on events, politics, business and more.

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer ...
United Kingdom United States Noel Clarke Eliav Barr Cristian Massacesi Company On Twitter

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
United Kingdom United States Isabella Zinck Susanne Schaffert Rachel Levine Novartis Pluvicto

Novartis Pharma AG: Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic
United States Isabella Zinck Susanne Schaffert Rachel Levine Oliver Sartor Nicole Zinsli Somm

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science